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Introduction
Rett syndrome (RTT) is one of the most common forms of intel-
lectual disability in young girls. After a period of normal devel-
opment, the disease emerges by the first 6–18 months of age 
and is characterized by loss of learned language skills, decelera-
tion of head growth, irregular breathing patterns, stereotypical 
hand-wringing, and profound cognitive impairment (1). RTT is a 
disorder of known genetic etiology, with the vast majority of cases 
the result of de novo mutations in the methyl-CpG–binding pro-
tein 2 (MECP2) gene (2). MeCP2 binds preferentially to symmet-
rically methylated CpG dinucleotides via its methyl-CpG–binding 
domain (MBD) and is thought to mediate transcriptional repres-
sion through the recruitment of corepressors, such as the SIN3 
transcription regulator family member A (SIN3A) and the nuclear 
receptor corepressor (NCoR) and silencing mediator of retinoic 
acid and thyroid hormone receptor (SMRT) corepressor complex-
es (3–7). Recent studies, however, have revealed that MeCP2-de-
pendent gene regulation is much more complex, with MeCP2 
activating or repressing gene expression depending on the cellular 
context, gene length, and signatures of DNA methylation (8–14).
Genetic reexpression of MeCP2 in symptomatic Mecp2-null 
mice leads to restoration of neuronal function and reversal of 
phenotypes, demonstrating that RTT is treatable, at least in mice, 
even at late stages of the disease (15). One leading approach to 
clinically restore MeCP2 function in patients is via gene therapy 
(16), a challenging endeavor, because MeCP2 expression levels 
must be precisely controlled, as both over- and underexpression 
lead to neurological phenotypes in humans and mice (17–22). In 
addition, gene therapy approaches may have limited feasibility in 
the case of dominant-negative mutations. Thus, a genotype-spe-
cific approach is needed to model the disorder and determine how 
different RTT-causing mutations disrupt MeCP2 function.
The majority of missense mutations identified in patients with 
RTT are clustered in the MBD and transcription repression domain 
(TRD) of MeCP2, with one of the most frequent mutations occur-
ring at residue T158, converting it to a methionine (MeCP2 T158M) 
or, in rare cases, alanine (T158A) (23). To determine the genetic 
contribution of the MeCP2 T158M mutation to RTT, we developed 
MeCP2 T158M–knockin (Mecp2T158M) mice and found that they 
recapitulate many clinical features of RTT. We further found that 
MeCP2 T158M levels failed to increase during postnatal develop-
ment, contributing, at least in part, to its reduced DNA binding. 
This raised the possibility that stabilizing MeCP2 T158M protein or 
increasing its expression might ameliorate disease phenotypes. To 
test this in vivo, we generated a Tg mouse line expressing MeCP2 
T158M throughout the CNS and found that elevation of MeCP2 
T158M expression restored the binding of mutant MeCP2 to DNA 
and, notably, improved many features of the disease. Furthermore, 
overexpression of MeCP2 T158M in Tg mice did not lead to the 
development of RTT-like phenotypes, ruling out the possibility that 
MeCP2 T158M shows dominant-negative effects. Finally, we found 
that the levels of MeCP2 T158M can be increased pharmacological-
ly with proteasome inhibitors. Together, these findings demonstrate 
that reduced levels of MeCP2 T158M at least partially underlie RTT 
pathology and provide a proof of principle that pharmacologic ele-
vation or stabilization of MeCP2 protein represents an effective 
approach  to treating patients with MBD missense mutations.
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Since heterozygous females are the more clinically relevant 
mouse model, we also characterized RTT-like phenotypes in female 
mice. We found that Mecp2T158M/+ heterozygous females weighed sig-
nificantly more than did Mecp2+/+ female littermates after 8 months 
of age (Figure 1E). Despite their increased body weight, Mecp2T158M/+ 
female mice were microcephalic (Figure 1F). Compared with hem-
izygous Mecp2T158M/y male mice, heterozygous Mecp2T158M/+ female 
mice developed similar RTT-like phenotypes, though they were 
less severe and had delayed progression (Figure 1G). In addition, 
Mecp2T158M/+ females lived considerably longer than did Mecp2T158M/y 
males, but also died prematurely, occasionally as a result of tonic- 
clonic seizures after routine handling (Figure 1H). Thus, both male 
and female Mecp2T158M mice display phenotypes similar to those of 
Mecp2-null mice (24, 25) and recapitulate many of the neurological 
deficits reminiscent of RTT.
MeCP2 T158M binds to DNA in a protein level–dependent man-
ner. T158 is located in the C-terminal portion of the MBD and is 
critical for stabilizing the tandem Asx-ST motifs and increasing 
the affinity of MeCP2 for methylated DNA (26). Further, it has 
been reported that mutation at T158 reduces the affinity of MeCP2 
for methylated DNA, leading to the pathogenesis of RTT (27, 28). 
Consistent with this notion, we found that MeCP2 T158M protein 
was diffusely localized in the nucleus, suggesting impaired bind-
ing of MeCP2 T158M to DNA (Figure 2A). However, in addition, 
we observed that the protein expression level of MeCP2 T158M 
was approximately 82% of WT MeCP2 expression at P0 or P1 (Sup-
plemental Figure 1B and Supplemental Figure 2B), but decreased 
to approximately 50% of WT levels at P7 and further decreased 
to approximately 35% of WT levels at P14, where it remained 
Results
Development and phenotypic characterization of Mecp2T158M mice. 
MeCP2 T158M is the most common missense mutation identified 
in individuals with classical RTT (23). To examine the role of this 
mutation in RTT etiology, we used a homologous recombination 
approach and generated knockin mice recapitulating this muta-
tion (Mecp2T158M mice) (Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI90967DS1). To facilitate the identification of mutant MeCP2 
protein, we fused a Tavi affinity tag (TEV protease cleavage and 
avidin binding) onto the C-terminus of MeCP2, allowing it to be 
biotinylated in vivo and identified with streptavidin (Supplemental 
Figure 1A). WT MeCP2-Tavi mice are phenotypically indistinguish-
able from WT mice up to 20 weeks of age, and both the tagged and 
untagged WT protein bind similarly to DNA, demonstrating that 
the tag itself does not affect MeCP2 function (B.S. Johnson, unpub-
lished observations). The presence of the T158M mutation was con-
firmed by sequencing (Supplemental Figure 1B) and probing brain 
lysates with a T158 site–specific antibody (Supplemental Figure 1C).
We next monitored T158M-knockin mice for the development of 
RTT-like phenotypes. Consistent with previous findings in Mecp2-null 
mice (24, 25), Mecp2T158M/y male mice weighed significantly less (Fig-
ure 1A) and had significantly reduced brain weights compared with 
Mecp2+/y male littermates (Figure 1B). Phenotypic scoring, which mea-
sures a range of RTT-like phenotypes, including gait abnormalities, 
motor deficits, and breathing (15), was performed on Mecp2T158M/y mice 
aged 4–12 weeks. We observed a marked, age-dependent increase in 
the phenotypic score for Mecp2T158M/y male mice leading to premature 
death at approximately 13 weeks (Figure 1, C and D).
Figure 1. Mecp2T158M mice display RTT-like phenotypes. (A) Body weights of Mecp2T158M/y male mice (n = 53, blue) were reduced relative to Mecp2+/y litter-
mate body weights (n = 29, black) at 4 weeks and thereafter. ****P < 0.0001, by Student’s t test. (B) Mecp2T158M/y male mice had reduced brain weights at 
P42 and P100 (n = 8 for both genotypes and ages). **P < 0.01 and ****P < 0.0001, by Student’s t test with Bonferroni’s post-hoc test. (C) Age-dependent 
presentation of RTT-like phenotypes in Mecp2T158M/y (n = 45) versus Mecp2+/y (n = 24) male mice. ****P < 0.0001, by Student’s t test.(D) Kaplan-Meier sur-
vival curve revealed that Mecp2T158M/y male mice had premature lethality (Mecp2+/y median survival >200 days, n = 35, vs. Mecp2T158M/y median survival = 92 
days, n = 39). (E) Body weight versus postnatal age for female Mecp2T158M/+ mice (n = 12) compared with Mecp2+/+ littermates (n = 10). Mecp2T158M/+ mice had 
significantly higher body weights at P250 or older. *P < 0.05, by Student’s t test. (F) Brain weights of female mice at P300 (n = 5 per genotype). **P < 0.01, 
by Student’s t test with Bonferroni’s post-hoc test. (G) Phenotypic scores of female Mecp2T158M/+ mice (n = 12) relative to scores for Mecp2+/+ littermates  
(n = 10). *P < 0.05, by Student’s t test. (H) Reduced survival of Mecp2T158M/+ (n = 76) compared with Mecp2+/+ (n = 14) female mice. Censored animals are 
indicated by a tick mark. All error bars represent the mean ± SEM.
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Figure 2. The binding of MeCP2 T158M to DNA is protein expression level 
dependent. (A) Immunohistochemical staining for MeCP2 in the cortex of male 
Mecp2T158M/y mice compared with Mecp2+/y littermates at P30. MeCP2 T158M 
staining is largely diffuse, without visible foci. Original magnification: ×100. (B) 
MeCP2 protein levels in whole brain from Mecp2T158M/y mice at P0, P7, P14, P21, 
P30, and P84, as compared with levels in Mecp2+/y controls (n = 3–4 per geno-
type). Quantification is relative to WT MeCP2 levels at each age and normalized 
to TBP to account for differences in loading. (C) MeCP2 protein levels in whole 
brain from Mecp2T158M/y and Mecp2+/y animals during development. Quantification 
is relative to P0 for each genotype and normalized to TBP (n = 3 per genotype and 
age). Despite similar protein levels at P0, WT MeCP2 levels steadily increased, 
while MeCP2 T158M levels declined and never rose to the levels of WT MeCP2 in 
adulthood. (D) ChIP-qPCR for MeCP2 and control IgG in whole brain from Mecp2+/y 
and Mecp2T158M/y littermates at P0 (top, n = 5 per genotype), P14 (middle, n = 3 per 
genotype), and P30 (bottom, n = 4 per genotypes). Binding of MeCP2 T158M to 
DNA was similar to that of WT MeCP2 at P0 but was reduced at P14 and P30. (E) 
ChIP-qPCR as in D plotted across age. Binding of MeCP2 T158M to DNA failed to 
increase with postnatal age. Statistical analyses in B–D were done by unpaired 
Student’s t test. Comparisons in E were done by 1-way ANOVA, followed by 
Tukey’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. 
All error bars represent the mean ± SEM.
Downloaded from http://www.jci.org on May 30, 2017.   https://doi.org/10.1172/JCI90967
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 8 9 2 jci.org   Volume 127   Number 5   May 2017
diffuse (Supplemental Figure 2F). Interestingly, in high-express-
ing FLAG-T158M-Dendra2 cell lines, MeCP2 localized to heter-
ochromatic foci with increased frequency. Together, these results 
demonstrate that MeCP2 T158M is capable of binding to methyl-
ated DNA in a protein level–dependent manner. Mutation at T158 
partially reduced the binding affinity of MeCP2 for methylated 
DNA in vivo and in vitro.
Generation and characterization of T158M-Tg mice. Since 
high-level expression of MeCP2 T158M in cultured cells rescues 
DNA binding, we examined the possibility that elevation of mutant 
MeCP2 expression in mice might restore MeCP2 function and 
ameliorate disease phenotypes. To test this, we first generated Tg 
mice that express MeCP2 T158M under the control of the mouse 
prion promoter (Prp), which drives broad expression in the CNS 
(32) (Figure 3A). Given that the e1 isoform of MeCP2 is abundant-
ly expressed in the brain (33, 34) and that knockout of this isoform 
fully recapitulates RTT-like phenotypes in mice (35), we generated 
Tg mice expressing MeCP2-e1 with the T158M mutation (T158M-
Tg). In addition, we included an N-terminal FLAG tag, allowing 
us to distinguish between endogenous and Tg MeCP2 protein. We 
obtained 2 Tg founder lines expressing Tg MeCP2 T158M protein 
at levels comparable to endogenous WT MeCP2 levels (Figure 3B). 
The presence of the T158M mutation was confirmed using a T158 
site–specific antibody (Figure 3C). We found that Tg T158M protein 
was highly expressed in the brain, with little to no detectable expres-
sion in the lung, liver, spleen, heart, kidney, or small intestine (Sup-
plemental Figure 3A). Within the brain, Tg T158M protein exhibited 
widespread distribution in different brain regions that was compa-
rable to the expression pattern of endogenous MeCP2 and consis-
tent with the broad activity of the prion promoter throughout the 
CNS (Figure 3D, and Supplemental Figure 3, B and C). Moreover, 
the expression of Tg MeCP2 T158M protein remained relatively sta-
ble throughout development (Figures 3E and Supplemental Figure 
3D) and retained the ability to interact with known binding part-
ners, such as SIN3A, transducin ȕ-like related protein (TBLR1), and 
histone deacetylase 3 (HDAC3) (Figure 3F).
T158M-Tg mice that overexpress WT MeCP2 by approxi-
mately 1-fold have enhanced motor and contextual learning by 10 
weeks of age, with seizures and hypoactivity becoming apparent 
by 20 weeks of age and premature death occurring in 30% of ani-
mals by 1 year of age (19). To examine whether T158M-Tg mice 
manifest a similar neurological phenotype, we monitored male 
T158M-Tg mice (Mecp2+/y T158M–Tg) over a period of 29 weeks 
(200 days). We found that Mecp2+/y T158M–Tg male mice were 
indistinguishable from their WT littermates with respect to body 
weight, brain weight, phenotypic score, and lifespan (Figure 3, 
G–J). Notably, Mecp2+/y T158M–Tg mice were viable until 2 years of 
age, with no premature death (data not shown). Female T158M-Tg 
mice (Mecp2+/+ T158M–Tg) were also comparable to WT Mecp2+/+ 
females in terms of body weight and phenotypic score (Supple-
mental Figure 3, E and F). Thus, our findings in both knockin and 
Tg mice suggest that MeCP2 T158M is a loss-of-function mutation, 
at least partially, and does not show dominant-negative effects.
Increasing MeCP2 T158M expression ameliorates RTT-like 
phenotypes in Mecp2T158M/y male mice. The generation of Tg mice 
expressing MeCP2 T158M without dominant-negative effects 
allowed us to test the possibility that increased expression of the 
relatively constant until 12 weeks of age (Figure 2B). In contrast, 
Mecp2 T158M mRNA expression remained unchanged over this 
age range (Supplemental Figure 2A), suggesting increased pro-
tein turnover. MeCP2 protein levels were also found to be reduced 
in fibroblasts derived from a female patient with RTT harboring 
the T158M mutation (27), in the absence of any change in mRNA 
(Supplemental Figure 2B). To determine whether MeCP2 T158M 
has reduced protein stability, we cultured cortical neurons isolat-
ed from Mecp2T158M/y and Mecp2+/y P0 pups and treated the neurons 
with cycloheximide (CHX) to block new protein synthesis. Where-
as WT MeCP2 protein expression remained unchanged upon CHX 
treatment, MeCP2 T158M protein was reduced by approximately 
75% after a 10-hour treatment, suggesting decreased MeCP2 
T158M protein stability (Supplemental Figure 2C). Moreover, we 
found that WT MeCP2 protein levels steadily increased postnatal-
ly, whereas MeCP2 T158M levels failed to increase at P7 and never 
reached those of WT MeCP2 in adulthood, despite similar protein 
expression levels in newborn pups (Figure 2C).
We hypothesized that the reduced levels of MeCP2 T158M pro-
tein might itself contribute to the impaired DNA binding and the 
consequent progression of disease phenotypes seen in Mecp2T158M 
animals. To investigate how MeCP2 T158M protein levels impact 
DNA binding, we performed ChIP, followed by quantitative PCR 
(ChIP-qPCR) throughout early development, comparing WT 
MeCP2 and MeCP2 T158M binding at a number of genomic loci 
that were found to be bound by MeCP2 in previous studies, includ-
ing the promoters of intercisternal A particles (IAPs), L1 retrotrans-
posons (LINE-1 RNAs), somatostatin (Sst), and the upstream and 
downstream regions of brain-derived neurotrophic factor (Bdnf) 
and nerve growth factor (Nr4a1), respectively (29, 30). At P0, an 
age at which the levels of WT MeCP2 and MeCP2 T158M are most 
similar (Figure 2B), MeCP2 binding at each target loci was compa-
rable between Mecp2+/y and Mecp2T158M/y animals (Figure 2D), sug-
gesting that MeCP2 T158M retains partial DNA-binding affinity, in 
agreement with previous in vitro studies (31). At P14, WT MeCP2 
showed an overall increase in binding relative to that detected at 
P0, and binding was further increased at P30 (Figure 2, D and E), 
consistent with the steady rise in WT MeCP2 levels during devel-
opment (Figure 2C). By contrast, the binding of MeCP2 T158M to 
DNA was significantly reduced relative to WT MeCP2 binding at 
both P14 and P30 at several loci (Figure 2, D and E), coincident 
with the overall reduced levels of this mutant protein at these ages 
(Figure 2B). These data suggest that the binding of MeCP2 T158M 
to DNA is at least in part dependent on its protein level. We further 
tested this in cultured cells by engineering Neuro2a (N2a) clonal 
cell lines stably expressing either WT MeCP2 or MeCP2 T158M. 
We also tagged both WT and mutant MeCP2 with an N-terminal 
FLAG tag and a C-terminal fusion of Dendra2, a photoconvert-
ible protein similar to GFP (FLAG-MeCP2-Dendra2 and FLAG-
T158M-Dendra2, respectively) to facilitate the visualization of 
MeCP2 (Supplemental Figure 2D). We then generated clonal lines 
that expressed varying levels of FLAG-MeCP2-Dendra2 or FLAG-
T158M-Dendra2 protein (Supplemental Figure 2E). Using immu-
nofluorescence to examine MeCP2 localization, we found that 
WT MeCP2 colocalized with heterochromatic foci in both low- 
and high-expressing FLAG-MeCP2-Dendra2 cells, while FLAG-
T158M-Dendra2, when expressed at low levels, remained largely 
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Figure 3. Generation and characterization of T158M-Tg mice. (A) Schematic of the construct used for transgenesis. Mecp2 T158M cDNA containing 
an N-terminal FLAG tag was placed under the control of the mouse prion promoter (Prp). (B) Western blot analysis of brain lysate from 2 T158M-Tg 
mouse lines (Tg2 and Tg3). FLAG-tagged Tg MeCP2 T158M (T158M-Tg) migrated slightly above endogenous MeCP2 levels. Graph shows quantification 
of T158M-Tg protein levels. Values were normalized to NeuN, and the results are shown as the percentage of endogenous MeCP2 (n = 4 for Tg2 and  
n = 5 for Tg3). (C) Whole-brain nuclear lysate from T158M-Tg mice probed with a T158 site–specific antibody confirmed the presence of the mutation. 
(D) Sagittal sections stained for MeCP2 and FLAG show a similar distribution pattern for endogenous WT MeCP2 and Tg MeCP2 T158M throughout 
the brain. Scale bar: 500 ȝm. (E) Western blot analysis of Tg MeCP2 T158M protein levels in young (P20) and old (P200) T158M-Tg animals. (F) Anti-
FLAG immunoprecipitates from Mecp2+/y T158M–Tg and Mecp2+/y whole brain were probed for the known MeCP2-interacting proteins SIN3A, TBLR1, 
and HDAC3. WB, Western blot. (G) Body weights of Mecp2+/y male mice (n = 22, black) compared with Mecp2+/y T158M–Tg male littermates (n = 15, 
yellow) up to 28 weeks of age. (H) Brain weights at P42 (n = 8 for each genotype), P100 (n = 8 for each genotype), and P200 (n = 5 for each genotype). 
(I) Phenotypic scores (n = 22 for Mecp2+/y mice and n = 15 for Mecp2+/y T158M–Tg mice) and (J) survival assessment (n = 21 for Mecp2+/y mice and n = 35 
for Mecp2+/y T158M–Tg mice) for Mecp2+/y T158M–Tg males and WT littermates. In each assay, the findings for T158M-Tg mice were indistinguishable 
from those of WT mice. All error bars represent the mean ± SEM.
Downloaded from http://www.jci.org on May 30, 2017.   https://doi.org/10.1172/JCI90967
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 8 9 4 jci.org   Volume 127   Number 5   May 2017
Downloaded from http://www.jci.org on May 30, 2017.   https://doi.org/10.1172/JCI90967
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 8 9 5jci.org   Volume 127   Number 5   May 2017
mutant protein might ameliorate disease phenotypes. To test 
this, we obtained animals expressing elevated levels of MeCP2 
T158M by breeding heterozygous Mecp2T158M/+ females with 
Mecp2+/y T158M–Tg males. From these crosses, we produced male 
animals of 4 genotypes: (1) Mecp2+/y, (2) Mecp2+/y T158M–Tg, (3) 
Mecp2T158M/y, and (4) Mecp2T158M/y T158M–Tg. The latter genotype, 
Mecp2T158M/y T158M–Tg, represents animals with increased lev-
els of MeCP2 T158M protein. Total MeCP2 protein expression 
in Mecp2T158M/y T158M–Tg males was roughly twice that of WT 
Mecp2+/y animals, but approximately 4.5-fold that of knockin 
Mecp2T158M/y littermates (Figure 4A).
Following phenotypic characterization similar to that per-
formed for Mecp2T158M mice, we found that Mecp2T158M/y T158M–Tg 
males appeared larger in size, were less hunched, and had smooth-
er coats than did Mecp2T158M/y littermates (Supplemental Figure 
4A). Notably, with a median survival of approximately 150 days, 
Mecp2T158M/y T158M–Tg mice lived approximately twice as long as 
their Mecp2T158M/y littermates (Figure 4B). Mecp2T158M/y T158M–Tg 
mice also showed increased body weight and brain weight relative 
to Mecp2T158M/y animals (Figure 4, C and D).
To examine whether genetically increasing MeCP2 T158M 
expression ameliorates behavioral deficits in Mecp2T158M/y mice, 
we subjected males of all 4 genotypes to a series of behavioral 
assessments. Given that motor dysfunction is a prominent fea-
ture of RTT, we measured locomotor activity using the open field 
assay. Consistent with our previous findings in Mecp2-null and 
MeCP2 T158A–knockin (Mecp2T158A) mice (27), Mecp2T158M mice 
show significantly reduced locomotion compared with their WT 
littermates. In contrast, Mecp2T158M/y T158M–Tg animals exhibited 
a marked improvement in locomotion, as measured by the total 
number of beam breaks (Figure 4E), distance traveled (Supple-
mental Figure 4B), and average speed (Supplemental Figure 4C) 
in the open field arena relative to Mecp2T158M/y mice. Moreover, 
Mecp2T158M/y mice performed significantly less well than did their 
WT littermates on the accelerating rotarod, consistent with previ-
ous reports (28). However, Mecp2T158M/y T158M–Tg mice performed 
similarly to WT littermates, demonstrating a near-complete res-
cue in motor coordination and motor learning (Figure 4F).
Another key feature of RTT is respiratory abnormalities. We 
therefore examined respiratory function using whole-body pleth-
ysmography. Mecp2T158M/y mice experienced episodes of irregular 
breathing and had significantly increased incidences of apneas 
compared with  Mecp2+/y and Mecp2+/y T158M–Tg mice. This is 
consistent with previous findings in Mecp2-null and Mecp2T158A 
mice (16, 36, 37) Notably, in Mecp2T158M/y T158M–Tg animals, we 
observed a rescue in overall breathing patterns and significantly 
reduced respiratory irregularity scores (Figures 4, G and H, and 
Supplemental Figure 4D). The number of apneas per hour, more-
over, was reduced by approximately 5-fold in Mecp2T158M/y T158M–
Tg mice compared with Mecp2T158M/y mice (Figure 4I).
Dysfunction in sensory information processing, measured 
as changes in visual or auditory event–related potentials (ERPs), 
has been observed in patients with RTT and in mouse mod-
els of RTT (27, 38–41). We therefore measured ERP respons-
es following the presentation of sound stimulation in awake, 
freely mobile mice. Similar to Mecp2T158A/y mice, Mecp2T158M/y 
mice showed a significant reduction in event-related power 
and phase-locking factor (PLF) responses across all measured 
frequencies compared with Mecp2+/y mice, indicating impaired 
information processing (Figures 4, J and K, and, Supplemental 
Figure 4E). Importantly, we found that Mecp2T158M/y T158M–Tg 
mice showed a partial rescue of auditory-evoked power and PLF 
responses, particularly at higher frequencies (Figures 4, J and K, 
and Supplemental Figure 4E). The auditory-evoked power and 
PLF responses of Mecp2+/y T158M–Tg mice were not statistical-
ly different from those of Mecp2+/y mice (Supplemental Figure 
4F). Taken together, our results show that augmenting the levels 
of MeCP2 T158M protein, despite its reduced affinity for DNA, 
substantially ameliorates motor, respiratory, and ERP deficits 
in male Mecp2T158M/y mice. In addition, Mecp2T158M/y T158M–Tg 
mice behaved similarly to their WT littermates in all behavior-
al assessments, consistent with the notion that MeCP2 T158M 
shows no dominant-negative effects.
Assessing the dosage effect of MeCP2 T158M expression on pheno-
typic rescue. Given the strict dosage requirements for WT MeCP2, 
a critical question from a therapeutic standpoint is understanding 
the extent to which overexpression of MeCP2 T158M protein might 
introduce detrimental effects. To address this, we investigated the 
effects of doubling the expression levels of MeCP2 T158M by breed-
ing the transgene to homozygosity, producing Mecp2T158M/y T158M–
Tg homozygous male mice (Mecp2T158M/y T158M–Tg/T158M-Tg). In 
Mecp2T158M/y T158M–Tg/T158M-Tg males, the total MeCP2 levels 
were approximately 3-fold those of WT Mecp2+/y male littermates, 
but approximately 8-fold those of knockin Mecp2T158M/y male mice 
(Supplemental Figure 5A). We found that Mecp2T158M/y T158M–Tg/
T158M-Tg homozygous animals had body weights, brain weights, 
locomotor activity, and motor coordination and learning that were 
similar to those of Mecp2T158M/y T158M–Tg heterozygous animals 
Figure 4. Tg elevation of MeCP2 T158M protein expression ameliorates 
behavioral deficits in male Mecp2T158M/y mice. (A) Western blot analysis 
of MeCP2 protein levels in brain nuclear lysate from male mice of all 4 
genotypes at 12 weeks of age. Dot plot indicates the total amount of 
MeCP2 protein in Mecp2+/y (n = 5, black), Mecp2+/y T158M–Tg (n = 6, yellow), 
Mecp2T158M/y (n = 7, blue), and Mecp2T158M/y T158M–Tg (n = 7, red) mice. MeCP2 
levels were quantified using ȕ-actin for normalization and are represent-
ed as the fold-change relative to Mecp2T158M/y. (B) Kaplan-Meier survival 
curve (n = 35, 21, 38, and 18 per genotype) shows increased lifespan in 
Mecp2T158M/y T158M–Tg animals (median survival of ~150 days) relative to 
that of Mecp2T158M/y mice (median survival of ~92 days). Censored animals 
are indicated by a tick mark. (C) Body weights (n = 14, 14, 16, and 12) and 
(D) brain weights (n = 7, 9, 9, and 13) at 12 weeks were partially rescued in 
Mecp2T158M/y T158M–Tg animals. (E) The number of beam breaks in an open 
field assay (n = 13, 13, 25, and 31) was significantly increased in Mecp2T158M/y 
T158M–Tg animals compared with Mecp2T158M/y animals at 10 weeks of age. 
(F) Rotarod performance of 12-week-old animals (n = 12, 20, 15, and 29). 
The impaired performance of Mecp2T158M/y mice was rescued in Mecp2T158M/y 
T158M–Tg animals. ****P < 0.0001, by 2-way ANOVA. (G) Representative 
plethysmographic tracings (time bar: 2 s). Red boxes delineate apneic 
episodes. (H) Respiratory irregularity scores and (I) number of apneas per 
hour (n = 9, 5, 10, and 10) at 8 weeks of age. Mecp2T158M/y T158M–Tg males 
had reduced respiratory irregularities and apneas relative to Mecp2T158M/y 
mice. Heatmaps indicating changes in (J) event-related power and (K) PLF 
in response to auditory stimulation in 10- to 14-week-old animals show 
rescue of information processing in Mecp2T158M/y T158M–Tg mice. Compar-
isons in A, C, D, E, H, and I were done using 1-way ANOVA, followed by 
Tukey’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001, and  
****P < 0.0001. All error bars represent the mean ± SEM. 
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of MeCP2 T158M expression, even at levels approximately 3-fold 
higher than WT MeCP2 levels, markedly improves behavioral per-
formance in Mecp2T158M/y male mice.
Increasing MeCP2 T158M expression ameliorates behavioral 
impairments in Mecp2T158M/+ female mice. Since RTT is primarily a 
female disorder, we next examined whether genetic elevation of 
(Supplemental Figure 5, B–E). Thus, low and high MeCP2 T158M 
transgene expression confers similar behavioral improvements in 
male mice. Further, these results indicate that an increased MeCP2 
T158M dosage is not deleterious and that MeCP2 T158M expres-
sion levels do not need to be as tightly controlled as do those of WT 
MeCP2. Taken together, these data demonstrate that Tg elevation 
Figure 5. Genetically increasing the expression of MeCP2 T158M protein improves behavioral phenotypes in female Mecp2T158M/+ mice. (A) Latency to fall 
in the rotarod task for 6-month-old Mecp2+/+ (n = 9, black), Mecp2+/+ T158M–Tg (n = 14, yellow), Mecp2T158M/+ (n = 9, blue), and Mecp2T158M/+ T158M–Tg (n = 22, 
red) female mice. The deficit in Mecp2T158M/+ mice was significantly more than that observed in Mecp2+/+ (**P < 0.01) and Mecp2T158M/+ T158M–Tg (*P < 0.05, 
by 2-way ANOVA) mice. (B) Representative images of paw placements on the treadmill surface for 7-month-old female mice of each genotype. (C) Stance 
and (D) propulsion times for the fore- and hind paws (n = 8, 5, 6, and 7 per genotype). Mecp2T158M/+ female mice had reduced stance and propulsion times in 
the hind paws. These deficits were rescued in Mecp2T158M/+ T158M–Tg littermates. (E) Representative plethysmographic tracings (time bar: 2 s). Red boxes 
delineate apneic episodes. (F) Average respiratory irregularity scores (n = 12, 6, 8, and 17 per genotype) and (G) number of apneas per hour (n = 13, 6, 9, 
and 17 per genotype) for 6- to 9-month-old female mice. Mecp2T158M/+ T158M–Tg females had significantly reduced respiratory irregularity scores relative to 
Mecp2T158M/+ mice. Comparisons in C, D, F, and G were done using 1-way ANOVA, followed by Tukey’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001. All error bars represent the ± SEM.
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6A). These results differ slightly from those in N2a cells, in which 
increased puncta formation in the high-expressing FLAG-T158M-
Dendra2 cell line was observed. The difference may lie in the fact 
that N2a cells are a tumor-derived cell line made up of phenotypi-
cally immature neurons that may not accurately recapitulate neu-
ronal features in the adult brain.
The majority of WT MeCP2 is tightly bound to chromatin in 
the nucleus and is extracted under high ionic conditions or nucle-
ase treatment. By contrast, mutation at T158 results in extraction of 
MeCP2 at lower salt concentrations because of the reduced affinity 
of MeCP2 for methylated DNA (27). To compare the subnuclear 
distributions of MeCP2 in Mecp2+/y, Mecp2T158M/y, and Mecp2T158M/y 
T158M–Tg animals, we performed subnuclear fractionation exper-
iments in cortical nuclei (Figure 6B). As expected, the bulk of WT 
MeCP2 is found in the chromatin fraction (Chr), with relatively 
little present in the nucleosolic fraction (Nuc). In Mecp2T158M/y ani-
mals, as shown previously, the overall levels of MeCP2 T158M were 
reduced, and MeCP2 T158M localization was predominantly nucle-
osolic, not chromatin bound. Similarly, in Mecp2T158M/y T158M–Tg 
animals, the majority of mutant protein was present in the nucle-
osolic fraction as opposed to the chromatin fraction, in agreement 
with the relatively diffuse pattern observed with IHC (Figure 6A). 
However, the levels of MeCP2 T158M in both the nucleosolic and 
chromatin-bound fractions were increased relative to their respec-
tive fractions in Mecp2T158M/y animals (Figure 6B). Thus, the overall 
elevated expression of MeCP2 T158M protein comprises both a 
nucleosolic pool and, to a lesser extent, a chromatin-bound pool.
To evaluate whether the increased chromatin-bound MeCP2 
T158M reflects increased MeCP2 binding to specific genomic loci, 
we next performed MeCP2 ChIP–quantitative PCR (ChIP-qPCR) 
on cortical tissue from Mecp2+/y, Mecp2T158M/y, and Mecp2T158M/y 
T158M–Tg animals (Figure 6C). In Mecp2+/y animals, MeCP2 
bound to known target loci within the Sst, Bdnf, Crh, and Nr4a1 
genes, the promoters of LINE-1 and IAP repeat elements, and, to 
a lesser extent, at the Gapdh promoter (29, 30, 45). By contrast, in 
Mecp2T158M/y animals, the binding of MeCP2 T158M to each locus 
was markedly reduced. Notably, in Mecp2T158M/y T158M–Tg ani-
mals, the binding of MeCP2 T158M was elevated overall relative 
to that seen in Mecp2T158M/y animals at each MeCP2 target site (Fig-
ure 6C). Together, these data demonstrate that increasing MeCP2 
T158M protein expression in vivo overcomes the DNA-binding 
defect associated with this mutant, leading to amelioration of 
RTT-like phenotypes.
Proteasome inhibition increases MeCP2 T158M protein levels. 
Having found that genetic overexpression of MeCP2 T158M res-
cues DNA binding and RTT-like phenotypes in mice, we next 
sought to increase MeCP2 T158M levels via a pharmacologi-
cal approach. We first sought to identify the molecular pathway 
responsible for MeCP2 T158M degradation. We therefore cultured 
N2a FLAG-MeCP2-Dendra2 clonal cell lines and treated them 
with various inhibitors of protein degradation pathways, including 
calpeptin (calpain inhibitor), 3-methyladenine (3-MA; autophagy 
inhibitor), ammonium chloride (NH
4
Cl; lysosome inhibitor), and 
MG132 (proteasome inhibitor). We found that MG132 increased 
FLAG-MeCP2-Dendra2 levels to the greatest extent (Figure 6D), 
indicating that the ubiquitin/proteasome pathway is the primary 
pathway by which MeCP2 is degraded. While we found a detect-
MeCP2 T158M expression also ameliorates RTT-like phenotypes 
in female mice. We first subjected female mice to the accelerating 
rotarod task. Consistent with findings in heterozygous Mecp2-null 
females (36, 42, 43), Mecp2T158M/+ females showed a significant-
ly reduced latency to fall from the rotarod compared with WT 
Mecp2+/+ littermates (Figure 5). By contrast, the rotarod perfor-
mance of Mecp2T158M/+ T158M–Tg female mice was nearly indistin-
guishable from that of WT Mecp2+/+ mice, indicating a full rescue 
of motor coordination and motor skill learning (Figure 5A). Given 
that gait abnormalities are a prominent feature of RTT, we next 
analyzed gait behavior in our female mice using the TreadScan 
system, which uses a transparent treadmill belt and high-speed 
camera to assess gait characteristics in rodent models. The system 
has been used previously to evaluate RTT-associated motor dys-
function (44). We found that Mecp2T158M/+ female mice showed a 
more uncoordinated gait overall relative to mice of the other gen-
otypes (Figure 5B) and had significantly reduced hind paw stance 
times, which is the duration the foot is in contact with the tread-
mill. This abnormality was rescued in Mecp2T158M/+ T158M–Tg ani-
mals (Figure 5C). Mecp2T158M/+ female mice, moreover, had signifi-
cantly reduced propulsion times in the hind paws relative to both 
Mecp2+/+ and Mecp2+/+ T158M–Tg females, a phenotype that was 
also rescued in Mecp2T158M/+ T158M–Tg mice (Figure 5D).
Given the characteristic breathing abnormalities in female 
patients with RTT and in mouse models of RTT, we next evaluated 
respiratory function using whole-body plethysmography. Similar 
to previous findings in heterozygous Mecp2-null female mice (16, 
36), Mecp2T158M/+ females had irregular breathing patterns and sig-
nificantly increased breathing irregularity scores compared with 
WT Mecp2+/+ mice. Notably, the irregularity scores of Mecp2T158M/+ 
T158M–Tg females were significantly reduced compared with 
those for Mecp2T158M/+ mice, indicating a significantly improved 
breathing pattern (Figure 5, E and F). Additionally, Mecp2T158M/+ 
T158M–Tg female mice had reduced numbers of apneas per hour 
compared with Mecp2T158M/+ females (Figure 5G). Though the latter 
assessment was not statistically significant because of 2 severe cas-
es, the majority of Mecp2T158M/+ T158M–Tg female mice did not have 
apneas (Figure 5G). Together, these data demonstrate that increas-
ing MeCP2 T158M protein expression also ameliorates a number of 
symptoms associated with RTT in female mouse models.
Genetic elevation of MeCP2 T158M expression in Mecp2T158M/y 
mice increases DNA binding. Given our findings in cultured N2a 
cells, we next tested the possibility that phenotypic amelioration 
might be mediated by increased binding of MeCP2 T158M to DNA 
in vivo. We thus performed IHC using anti-MeCP2 antibodies to 
assess the in vivo binding pattern of MeCP2 in all 4 genotypes 
of male mice (Figure 6A). Consistent with our previous findings, 
WT MeCP2 showed a punctate pattern of staining, reflecting the 
binding of MeCP2 to heterochromatic foci, while MeCP2 T158M 
showed a diffuse pattern, with no observed puncta. In contrast, 
Mecp2T158M/y T158M–Tg mice showed increased MeCP2 staining 
intensity compared with Mecp2T158M/y animals, consistent with ele-
vated MeCP2 T158M protein expression. In addition, we observed 
an increased incidence of MeCP2 colocalization with heteroch-
romatic foci in Mecp2T158M/y T158M–Tg animals compared with 
Mecp2T158M/y littermates, supporting the idea that MeCP2 T158M 
binds to DNA in an expression level–dependent manner (Figure 
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MeCP2 T158M expression increased DNA binding and improved 
behavioral phenotypes and the overall health of both male and 
female Mecp2T158M mice. To our knowledge, these findings are the 
first to implicate mutant MeCP2 protein expression level as a con-
tributing factor in RTT pathogenesis and reveal the targeting of 
MeCP2 protein expression or stability as a potential therapeutic 
approach for the treatment of RTT.
Several therapeutic approaches for treating RTT are being 
developed (43, 46–48), with adeno-associated virus–mediated 
(AAV-mediated) gene therapy at the forefront (16). A longstand-
ing theoretical concern for gene therapy is that patient-associated 
mutations may exert dominant-negative effects and that this 
would limit the function of the virally delivered WT copy. Giv-
en that patients with RTT are mosaic females, in which approx-
imately half of the cells express the WT Mecp2 allele, while the 
other half express the mutant allele, reactivation of the WT copy 
of Mecp2 on the inactive X chromosome (Xi) has been proposed as 
another potential strategy to treat the disorder. However, as with 
gene therapy approaches, it is also critical to determine in this 
context whether RTT-causing mutations act in a dominant-neg-
ative fashion, since both WT and mutant copies will be expressed 
in the same cell upon reactivation of the Xi. Thus, to determine 
the extent of a potential therapeutic benefit using these strate-
gies, a necessary first step is to assess whether RTT-associated 
mutations have dominant-negative effects.
Previous studies also reported that MeCP2 expression levels 
must be precisely controlled, with even a 1-fold increase in WT 
levels resulting in neurological phenotypes (17–22). We found that 
male and female T158M-Tg mice showed no behavioral abnormal-
ities or reduced longevity, suggesting that Tg T158M protein pro-
duces no dominant-negative effects on endogenous WT MeCP2. 
The T158M allele may thus be considered a partial loss of func-
tion. Thus, our data provide support for gene therapy approach-
es in patients with mutations at T158. Our data also support the 
idea that reactivation of the silenced Mecp2 allele, either WT or 
T158M, would be beneficial. Importantly, we observed no delete-
rious effects on Mecp2T158M/y mice expressing MeCP2 levels approx-
imately 3-fold higher than those in WT mice; in fact, the level of 
phenotypic improvement was similar in Mecp2T158M/y animals with 
1 or 2 copies of the Mecp2 T158M transgene. This implies a poten-
tially broader dosage window for therapeutic efficacy than expect-
ed from previous studies, an encouraging observation for future 
pharmacologic interventions. We are aware that our Mecp2T158M/y 
T158M–Tg mice did not exhibit a complete rescue of RTT-like 
phenotypes. This could be due to the fact that T158M-Tg protein 
is only expressed in neuronal cells in the CNS, but is missing astro-
cytes and other non-neuronal cells (49, 50). In addition, MeCP2 
T158M, even though expressed at higher levels than WT MeCP2, 
may not fully function as a WT protein.
Interestingly, we found that the average respiratory irregu-
larity scores of Mecp2T158M/+ females were higher than those of 
Mecp2T158M/y males and those previously reported for heterozygous 
Mecp2-/+ females (16, 51). Female patients with RTT are known to 
exhibit significant autonomic instability that manifests, in part, as 
ventilatory timing irregularities, including breath holding, apneas, 
tachypnea, and hyperpneas (52). Mecp2T158M/+ female mice in the 
present study showed marked respiratory variability, with greater 
able increase in WT FLAG-MeCP2-Dendra2 levels after 24 hours 
of MG132 treatment, elevated FLAG-T158M-Dendra2 levels 
were detectable after 7 hours (Figure 6E), reflecting the reduced 
stability of MeCP2 T158M. Notably, treatment with increasing 
concentrations of MG132 led to a dose-dependent increase in 
FLAG-T158M-Dendra2 levels (Figure 6F). We also observed a 
dose-dependent increase in MeCP2 T158M levels with the more 
specific proteasome inhibitor lactacystin (Supplemental Figure 6).
To examine whether endogenous MeCP2 T158M is also stabi-
lized by proteasome inhibition, we cultured cortical neurons from 
Mecp2T158M/y and Mecp2+/y animals and treated them with MG132 
for 4 and 8 hours. We found that MeCP2 T158M levels signifi-
cantly increased after 8 hours, while WT MeCP2 levels remained 
relatively unchanged, consistent with the increased stability of the 
WT protein (Figure 6G). Thus, MeCP2 T158M protein can be sta-
bilized pharmacologically with proteasome inhibitors, revealing 
the ubiquitin/proteasome pathway as a pathway to target in the 
treatment of RTT.
Discussion
A major advance in the RTT field is the finding that restoration of 
endogenous MeCP2 expression in symptomatic Mecp2-null mice 
leads to reversal of RTT-like phenotypes, supporting the possi-
bility that RTT is a treatable condition. Despite this remarkable 
achievement, determining how to restore normal MeCP2 function 
in RTT patients remains a challenge. In this study, we found that 
the binding of MeCP2 T158M to methylated DNA is at least in part 
dependent on its protein expression level. This prompted us to test 
whether increasing the expression of the mutant protein might 
overcome to a degree the reduced affinity of this mutant for DNA 
and partially restore MeCP2 function. Indeed, Tg elevation of 
Figure 6. Tg elevation of MeCP2 T158M expression increases DNA 
binding. (A) IHC for MeCP2 in brain sections from animals of the indicated 
genotype at 12 weeks. Scale bar: 20 ȝm. Original magnification: ×63 with 
digital zoom. (B) Western blot of nucleosolic (Nuc) and chromatin-enriched 
(Chr) proteins in cortices from Mecp2+/y, Mecp2T158M/y, and Mecp2T158M/y 
T158M–Tg animals at 12 weeks. Graph shows the quantification of MeCP2 
levels in nucleosolic and chromatin fractions normalized to TBP. Values 
are represented as the fold-change relative to nucleosolic MeCP2 from 
Mecp2+/y animals (n = 3 per genotype). **P < 0.01, ***P < 0.001, and  
****P < 0.0001, by 2-way ANOVA, followed by Sidak’s multiple compar-
isons test. (C) MeCP2 ChIP-qPCR in cortices from 12-week-old Mecp2+/y, 
Mecp2T158M/y, and Mecp2T158M/y T158M–Tg animals at the indicated loci 
revealed significantly increased MeCP2 binding in Mecp2T158M/y T158M–Tg 
animals at several loci (n = 3–5 biological replicates). *P < 0.05, by 1-way 
ANOVA, followed by Tukey’s post-hoc test. (D) FLAG-MeCP2-Dendra2 
protein levels following treatment with inhibitors of protein degradation 
pathways. MG132 increased the levels of MeCP2 to the greatest extent. 
Values were normalized to ȕ-actin and are represented as the fold change 
relative to vehicle-treated cells (n = 3–5 per condition). (E) Time course 
of MG132 treatment in FLAG-T158M-Dendra2 and FLAG-MeCP2-Dendra2 
N2a cell lines (n = 3 biological replicates). (F) FLAG-T158M-Dendra2 levels 
following treatment with increasing concentrations of MG132 (n = 3 per 
condition). (G) P0 plus 3-DIV cortical cultures from Mecp2+/y and Mecp2T158M/y 
animals treated with vehicle or 20 ȝM MG132 for 4 and 8 hours (n = 3 per 
genotype). Quantifications in E–G were performed by normalizing to the 
TBP loading control; values are shown as the fold-change relative to t0. 
Comparisons in D–G were done using 1-way ANOVA, followed by Dun-
nett’s multiple comparisons test. *P < 0.05 and **P < 0.01. All error bars 
represent the mean ± SEM.
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believe our findings represent the first step toward the development 
of a tailored therapeutic approach for individuals bearing missense 
mutations in the MBD and provide support for the development of 
personalized medicine to treat RTT and other genetic diseases.
Methods
Generation of Mecp2T158M- and T158M-Tg mice
The targeting construct used to generate Mecp2T158M mice was similar 
to that described previously (27). Threonine 158 was mutated to methi-
onine using the QuikChange Site-directed Mutagenesis Kit (Agilent 
Technologies). The locus was engineered to contain a 23–amino acid 
Tavi affinity tag that contains a biotinylation consensus motif, allowing 
for BirA-dependent biotinylation of MeCP2. The targeting construct 
was linearized using NotI and electroporated into sv129 mouse embry-
onic stem (ES) cells. Correctly targeted clones were identified by PCR 
screening, verified by Southern blotting, and injected into C57BL/6 
blastocysts and subsequently implanted into pseudopregnant females. 
Resulting chimeras were mated with C57BL/6 EIIa-Cre for embryonic 
deletion of the neomycin (Neo) cassette and subsequently backcrossed 
with C57BL/6 mice for at least 5 generations. Mecp2T158M mice were 
obtained from The Jackson Laboratory (stock no. 029642).
To generate FLAG-Mecp2T158MTg (T158M-Tg), Mecp2-e1 cDNA from 
mice was mutagenized to incorporate the T158M mutation and engi-
neered to contain an N-terminal FLAG tag. The resulting cDNA was 
subcloned into the XhoI site of the MoPrP.Xho vector (32), linearized 
with NotI, and gel purified. The construct was microinjected into the 
pronuclei of fertilized C57BL/6 eggs and implanted into pseudopreg-
nant female mice. Screening for Tg founders was performed by PCR 
genotyping using the primers described below. Tg mice were main-
tained on a C57BL/6 background.
Animal husbandry
Mecp2T158M/y mice were PCR genotyped using the following primers that 
span the Tavi tag: forward, 5′-CACCCCGAAGCCACGAAACTC-3′; 
reverse, 5′-TAAGACTCAGCCTATGGTCGCC-3′. Tg mice were gen-
otyped using primers (forward, 5′-GATCTGCTGGAAAGTATGATG-
TATATTTG-3′; reverse, 5′-CAACAAGTTTCCCAGGGCTC-3′) that 
span an MeCP2 intron, giving rise to 2 bands (~320 and 808 bp) in 
Tg animals and 1 band (808 bp) in WT animals. Male T158M-Tg mice 
were crossed with Mecp2T158M/+ or Mecp2T158M/+ T158M–Tg females to 
generate Mecp2T158M/y T158M–Tg or Mecp2T158M/+ T158M–Tg/T158M-
Tg animals, respectively. Mice were housed under a 12-hour light/12-
hour dark cycle, with ad libitum access to food and water.
Nuclear extracts
Brain nuclear extracts were prepared by dounce homogenization in lysis 
buffer containing 10 mM HEPES (pH 7.9), 0.5% NP-40, 1.5 mM MgCl
2
, 
and 10 mM KCl. Nuclei were collected, washed, and resuspended in buf-
fer composed of 20 mM HEPES (pH 7.9), 500 mM KCl, 1.5 mM MgCl
2
, 
0.2 mM EDTA, and 10% glycerol. Samples were rotated for 2 hours and 
ultracentrifuged at 106,000 g for 30 minutes at 4°C, and supernatants 
were subjected to quantitative infrared (IR) Western blotting using the 
Odyssey Infrared Imaging System (LI-COR Biosciences).
The following antibodies were used in this study: serum direct-
ed against the C-terminal region of MeCP2 (55); MeCP2 T158 site– 
specific serum (27); ȕ-actin (Abcam; Ab8226); NeuN (EMD Millipore; 
periods of tachypnea fluctuating with apneas, resulting in higher 
irregularity scores than previously observed in Mecp2–/+ female 
mice (51). The mean irregularity scores of WT and T158M-Tg 
males and females are similar to scores reported previously for 
WT animals (37, 51, 53), while Mecp2T158M/y male mice have irregu-
larity scores similar to those reported for Mecp2–/y and Mecp2R168X/y 
males (51, 53). An important difference, we believe, lies in the ages 
of the female and male mice used in these studies. In our study, 
the Mecp2T158M/y males were analyzed for breathing abnormalities 
at approximately 2 months of age, while the Mecp2T158M/+ females 
were measured at 6 to 9 months of age. The Mecp2–/+ females ana-
lyzed previously were between 9.8 and 14.5 months of age (51). 
Given previous findings that abnormal breathing patterns improve 
with advanced age in both patients with RTT and mouse models 
of RTT (37, 54), the severity of respiratory phenotypes, like oth-
er RTT-like behavioral abnormalities, greatly depends on the age 
at the time of measurement. Other factors, such as the particular 
MeCP2 mutation and the pattern of X-chromosome inactivation 
(XCI), also play important roles in female phenotypic severity.
Our findings also point to several new clinically feasible 
approaches to potentially restore MeCP2 function, thereby tack-
ling the root cause of the disorder. We show that mutation at T158 
destabilizes MeCP2 protein, resulting in its degradation, and that 
elevating the levels of mutant protein reverses numerous disease 
phenotypes. One potential strategy to increase MeCP2 T158M pro-
tein levels is to selectively inhibit its degradation. Here, we have 
identified the ubiquitin/proteasome pathway as the one by which 
MeCP2 T158M is degraded, highlighting this pathway as a poten-
tial drug target. Although it is conceivable that treatment with pro-
teasome inhibitors may provide clinical benefit to patients, the lack 
of brain-penetrant proteasome inhibitors could complicate deliv-
ery efforts. Proteasome inhibitors, moreover, target many cellular 
proteins and would exert many widespread, nonspecific effects. 
Future work directed at identifying the specific proteins involved 
in MeCP2 T158M turnover, such as the MeCP2 T158M–specific E3 
ubiquitin ligase, is necessary to further refine potential therapeu-
tic targets. High-throughput compound screens, moreover, can 
be used to identify compounds that stabilize MeCP2 T158M pro-
tein. Aside from inhibiting degradation, an alternative therapeutic 
strategy is to increase Mecp2 T158M expression at either the tran-
scriptional or translational level. Thus, utilizing CRISPR activation 
(CRISPRa) technology and AAV delivery vehicles to target tran-
scriptional activators to the endogenous Mecp2T158M allele to boost 
transcription might be a feasible in vivo approach.
Several hundred patient-associated MeCP2 mutations span-
ning the entire protein have been identified. These mutations 
include missense, frameshift, nonsense, and splice-site mutations 
(RettBASE, http://mecp2.chw.edu.au). Notably, missense muta-
tions in the MBD constitute approximately 25% of all RTT cases, 
underscoring the importance of this domain for proper MeCP2 
function. We have recently found that another frequent RTT- 
associated missense mutation in the MBD, MeCP2 R106W, also has 
reduced protein stability (B.S. Johnson, unpublished observations), 
suggesting that mutations in the MBD might destabilize MeCP2 in a 
general fashion. If this is the case, therapies that stabilize or increase 
the expression of mutant MeCP2 have the potential to benefit many 
patients, not just those with MeCP2 T158M mutations. Thus, we 
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mM Tris-HCl, pH 8.1, 250 mM LiCl, 0.5% NP-40, 0.5% DOC, and 
1 mM EDTA); and twice with Tris-EDTA (TE). Chromatin was elut-
ed with elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA, and 
1% SDS, wt/vol) and reverse cross-linked overnight at 65°C, followed 
by treatment with RNase A for 30 minutes at 42°C and proteinase K 
for 3 hours at 55°C. DNA was extracted twice with phenol/chloroform 
and once with chloroform, and ethanol was precipitated. qChIP was 
performed in duplicate on an ABI 7900 instrument (Thermo Fisher 
Scientific) using SYBR Green detection. Serial dilutions of input DNA 
were used to generate a standard curve for each primer pair.
ChIP primers
The following ChIP primers were used: IAP: forward, 5′-GCTTTC-
GTTTTTGGGGCTTGG-3′; reverse, 5′-CTTACTCCGCGTTCTCAC-
GAC-3′; LINE-1: forward, 5′-CAATCGCGTGGAACTTGAGAC-3′; 
reverse, 5′-GACTCAGCTGGCAAGGTAGC-3′; Sst: forward, 5′-CATT-
GACAGGTACCCAACTGA-3; reverse, 5′-CAGCCACATAGGAGCA-
CACTT-3′; Crh: forward, 5′-TCATAAGAAACCCTTCCATTTTCG-3′; 
reverse, 5′-TGAATCTCACATCCAATTATATCAACA-3′; Bdnf –6.6 kb: 
forward, 5′-CAGCACAGCCTGAAACGTAA-3′; reverse, 5′-TTTG-
GAGTGGAGCCCTTAGA-3′; Nr4a1 +7.4 kb: forward, 5′-ACTTGG-
TACCCCCTCCACCTA-3′; reverse, 5′-GCAGGGGTCAGAAAGA-
CAATG-3′; and Gapdh: forward, 5′-TCCCCTCCCCCTATCAGTTC-3; 
reverse, 5′-GACCCGCCTCATTTTTGAAA-3′.
RT-qPCR
RNA was extracted with TRIzol Reagent (Invitrogen, Thermo Fisher 
Scientific) and treated with TURBO DNase (Ambion, Thermo Fish-
er Scientific). Reverse transcription reactions were performed with 
Superscript III (Invitrogen, Thermo Fisher Scientific) using random 
hexamer priming. Results were quantified on an ABI 7900 system 
using SYBR Green technology. All RNA expression levels were nor-
malized to Gapdh.
RT-qPCR primers
The following RT-PCR primers were used: Mecp2: forward, 5′-CAT-
ACATAGGTCCCCGGTCA-3′; reverse, 5′-CAGGCAAAGCAGAAA-
CATCA-3′; Gapdh: forward, 5′-GATGCCCCCATGTTTGTGAT-3′; 
reverse, 5′-GGTCATGAGCCCTTCCACAAT-3′; MECP2: forward, 
5′-TTCACGGTAACTGGGAGAGG-3′; reverse, 5-GGAGCTTC-
CCAGGACTTTTC-3′; and GAPDH: forward, 5′-GAAATCCCATCAC-
CATCTTCCAGG-3′; reverse, 5′-GAGCCCCAGCCTTCTCCATG-3′.
Co-IP
Co-IPs were performed as described previously, with some modifica-
tions (7). Briefly, hindbrains were dounce homogenized in 5 ml NE10 
buffer (20 mM HEPES, pH 7.5, 10 mM KCl, 1 mM MgCl
2
, 0.1% Triton 
X-100, and 15 mM ȕ-mercaptoethanol), 10 times using a loose pestle 
and 10 times using a tight pestle. Nuclei were pelleted, washed, and 
incubated with 250 units benzonase (Sigma-Aldrich) for 5 minutes at 
room temperature. Nuclei were then resuspended in 1 ml NE150 buf-
fer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM KCl, 1 mM MgCl
2
, 
0.1% Triton X-100, and 15 mM ȕ-mercaptoethanol) and rotated for 
2 hours at 4°C. Lysates were centrifuged at 16,000 g, and the super-
natant was precleared for 2 hours with protein A agarose beads. Pre-
cleared supernatants were incubated with Anti-FLAG M2 Affinity 
Gel (Sigma- Aldrich) overnight. Bead-bound immune complexes were 
MAB377); TATA-binding protein (TBP) (Cell Signaling Technology; 
8515S); H3 (EMD Millipore; 06-755); GAPDH (Thermo Fisher Sci-
entific; MA5-15738); FLAG (Sigma-Aldrich; F3165); SIN3A (Thermo 
Fisher Scientific; PA1-870); HDAC3 (Santa Cruz Biotechnology Inc.; 
SC-11417); and TBLR1 (Bethyl Laboratories; A300-408A).
Subnuclear fractionation
To prepare nucleoplasm-enriched proteins, cortices were dounce 
homogenized in 5 ml NE10 buffer (20 mM HEPES, pH 7.5, 10 mM 
KCl, 1 mM MgCl
2
, 0.1% Triton X-100, and 15 mM ȕ-mercaptoetha-
nol) 30 times using a loose pestle. The resulting nuclei were washed 
with NE10 buffer and rotated in NE300 buffer (20 mM HEPES, pH 
7.5, 300 mM NaCl, 10 mM KCl, 1 mM MgCl
2
, 0.1% Triton X-100, and 
15 mM ȕ-mercaptoethanol) for 1 hour at 4°C. Samples were centri-
fuged at 500 g for 5 minutes, and the supernatant, which represents 
the nucleosolic fraction, was collected and saved. The insoluble pel-
let, consisting of the chromatin-bound fraction, was washed in NE150 
buffer and incubated with 500 units of benzonase (Sigma-Aldrich) for 
5 minutes at room temperature. The pellet was then resuspended in 50 
ȝl NE150 buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM KCl, 
1 mM MgCl
2
, 0.1% Triton X-100, and 15 mM ȕ-mercaptoethanol) and 
rotated for 1 hour at 4°C. Samples were centrifuged at 16,000 g, and 
the supernatant was collected as the chromatin-bound fraction.
IHC
IHC was performed essentially as previously described (27). Briefly, 
mice were deeply anesthetized with 1.25% (wt/vol) avertin and tran-
scardially perfused with 4% paraformaldehyde (wt/vol), and tissue 
was postfixed overnight at 4°C. Tissue was sectioned coronally or 
sagittally at a thickness of 20 ȝM. IHC was performed using a rab-
bit anti-serum against MeCP2 (1:1,000) or a rabbit antibody against 
the FLAG epitope (Sigma-Aldrich; F4725; 1:1,000). All images were 
acquired using a Leica confocal microscope, with identical settings 
for laser power, detector gain amplifier offset, and pinhole diameter 
in each channel.
ChIP
Mouse cortices were homogenized in buffer containing 100 mM 
HEPES (pH 7.5), 100 mM NaCl, 1 mM EDTA, and 1 mM EGTA and 
crosslinked for 10 minutes at room temperature with 1% formalde-
hyde, followed by quenching with 0.125 M glycine. Cells were lysed in 
cell lysis buffer (50 mM HEPES, pH 7.5, 140 mM NaCl, 1 mM EDTA, 
1 mM EGTA, 0.25% Triton X-100, 0.5% NP-40, and 10% glycerol) 
for 10 minutes on ice, and nuclei were collected and lysed in 10 mM 
Tris (pH 8.0), 1% SDS, 1 mM EDTA, and 1 mM EGTA. The SDS con-
centration was diluted to 0.625%, and DNA shearing was performed 
on a Bioruptor instrument (Diagenode; five 10-minute cycles: 30 sec-
onds on, 30 seconds off). Buffer conditions were adjusted to contain 
150 mM NaCl, 0.1% SDS, and 0.5% Triton X-100, and chromatin was 
precleared with Protein A Dynabeads (Invitrogen, Thermo Fisher Sci-
entific). Immunoprecipitation was performed using 32 ȝl Protein A 
Dynabeads and 8 ȝg goat affinity-purified antibody against the C-ter-
minus of MeCP2 or preimmune goat IgG. Beads were washed twice 
with low-salt buffer (150 mM NaCl, 50 mM HEPES, pH 7.5, 0.1% sodi-
um deoxycholate [DOC], 1% Triton X-100, and 1 mM EDTA); once 
with high-salt buffer (500 mM NaCl, 0.1% DOC, 50 mM HEPES, 
pH 7.5, 1% Triton X-100, and 1 mM EDTA); once with LiCl buffer (10 
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Plethysmography
A whole-body plethysmograph (Buxco II; DSI) allowed mice to assume 
natural postures and movement, during which apneas and respirato-
ry regularity were assessed. The plethysmograph system, calibrat-
ed to 1-ml volume, provided constant air exchange at 1 liter/minute. 
Ambient temperatures within the chamber ranged between 24°C and 
24.5°C. Mice were given 20 minutes to explore the chamber and were 
then recorded for 20 minutes of quiet wakefulness breathing. Air-
flow signals were recorded and analyzed using FinePointe Software 
(version 2.0.3.1; DSI). Apneas were defined as a cessation of airflow 
for more than 1 second (37) and were analyzed as the total number of 
apneas/time, expressed as apneas/hour. The respiratory frequency 
irregularity was defined as previously described (56) using the vari-
ance of the absolute values of T
TOTn
– T
TOTn+1
/T
TOTn+1
, where T
TOT
 equals 
the total respiratory cycle time.
ERP recordings
Each mouse was deeply anesthetized (1%–2% isoflurane) and mount-
ed in a stereotaxic frame with nonpuncturing ear bars. Three stain-
less steel electrodes, mounted in a single headstage, were aligned to 
the sagittal axis of the skull. A stainless steel recording electrode was 
placed 2.0 mm posteriorly and 2.0 mm left laterally relative to bregma, 
at a depth of 1.8 mm. Ground and reference electrodes were placed 
anterior to the hippocampal electrode at distances of 1.0 mm and 
2.0 mm, respectively. The headstage was then fixed to the skull with 
screws and dental acrylic.
ERP recordings were performed on freely mobile, nonanes-
thetized 10- to 14-week-old mice in their home cage environment 
after a 20-minute acclimation to the recording room. For local field 
potential recordings, neural signals were acquired using a Cheetah 
Data Acquisition System (Neuralynx; Digital Lynx 4SX; 2.0 kHz 
sample rate). Auditory stimuli consisting of a series of 250 white-
noise pips (10-ms duration, 85-dB sound pressure level [SPL], 0.25 
Hz frequency) were presented through speakers on the recording 
chamber ceiling. Stimuli were calibrated using a sound pressure 
meter. Because of the frequency response of speakers, white noise 
has a corresponding bandwidth of 700 to 20,000 kHz. Analyses of 
event-related power and PLF were performed in a manner similar 
to that described previously using wavelet methods with custom 
C routines (41).
For statistical analysis, event-related power and PLF were sepa-
rated into frequency ranges, with the mean power or PLF calculated 
between frequencies: į, 2–4 Hz; ș, 4–8 Hz; Į, 8–12 Hz; ȕ, 12–30 Hz; 
Ȗlow, 30–50 Hz; Ȗhigh, 50–90 Hz; and İ, 90–140 Hz. Statistical sig-
nificance was assessed using permutation tests based on t statistics 
and false-discovery correction made using the q-value methodology 
as previously described (57).
Phenotypic scoring
Mice were monitored for the development of RTT-like phenotypes as 
described previously (15).
Animal behavior
All animal behavioral studies were performed by female handlers 
blinded to genotype. Mice were allowed to habituate to the testing 
room for at least 30 minutes prior to testing, with each test performed 
at the same time of day.
washed with buffer composed of 20 mM HEPES (pH 7.5), 150 mM 
NaCl, 0.1% Triton X-100, 10% glycerol, and 0.2 mM EDTA. FLAG 
proteins and their interacting proteins were eluted with 100 ȝg/ml 
FLAG peptide for 1 hour at 4°C and resolved via SDS-PAGE.
Primary neuronal culture
Cortices from P0/P1 pups were dissected under a stereoscope and 
digested with trypsin (0.25% wt/vol) for 20 minutes at 37°C. The tryp-
sin was inactivated with plating media, and cortices were triturated 
and plated at a density of 1.0 × 106 to 1.5 × 106 cells per well of a 12-well 
dish coated with 0.01% poly-L-lysine (Sigma-Aldrich). Cultures were 
maintained in neurobasal medium supplemented with B27, 1× Gluta-
max (Gibco, Thermo Fisher Scientific), 0.5% D-glucose, 100 ȝg/ml 
Primocin (InvivoGen), and 10% FBS.
After 3 days in vitro (DIV), cells were treated with 100 ȝg/ml cyclo-
heximide or 20 ȝM MG132 for the indicated durations (Supplemental 
Figure 2C and Figure 6G) and harvested. Cells were lysed in NE10 
buffer (20 mM HEPES, pH 7.5, 10 mM KCl, 1 mM MgCl
2
, 0.1% Tri-
ton X-100, and 15 mM ȕ-mercaptoethanol). The resulting nuclei were 
incubated with NE300 buffer (20 mM HEPES, pH 7.5, 300 mM NaCl, 
10 mM KCl, 1 mM MgCl
2
, 0.1% Triton X-100, and 15 mM ȕ-mercap-
toethanol) for 1 hour on ice. Samples were centrifuged at 500 g for 5 
minutes, the supernatant was collected, and the proteins were resolved 
via SDS-PAGE.
Cell culture
Mouse N2A neuroblastoma and HEK 293T cells were cultured in 
DMEM containing 10% FBS (Invitrogen, Thermo Fisher Scientific), 
2% penicillin-streptomycin, and 1% sodium pyruvate.
Constructs
The MeCP2 LEMPRA (lentivirus-mediated protein-replacement assay) 
plasmid has been described previously (55). Modifications to the con-
struct included the removal of the GFP expression cassette and incor-
poration of an N-terminal FLAG tag and a C-terminal Dendra2 fusion 
in-frame with the MeCP2 coding sequence. QuikChange site-directed 
mutagenesis was used to introduce the MeCP2 T158M mutation.
Lentivirus production
Lentiviruses were produced by cotransfection of HEK293T cells 
with the FLAG-MeCP2-Dendra2 or FLAG-T158M-Dendra2 plasmid, 
together with the helper plasmids ǻ8.9 and VSV-G. N2a cells were 
seeded in a 6-well dish at a concentration of 1 × 105 cells/ml. The fol-
lowing day, 1 ml filtered virus was added to each well, together with 2 
ml fresh media and 16 ȝg polybrene and incubated at 37°C. The media 
were changed 24 hours later, and the next day, lentivirus-infected 
N2a cells were singly sorted according to GFP into 96-well plates and 
expanded to generate clonal cell lines.
Immunofluorescence
N2a lines stably expressing FLAG-MeCP2-Dendra2 or FLAG-T158M-
Dendra2 were grown on gelatin-coated coverslips. Cells were washed 
in PBS and fixed in 4% formaldehyde for 20 minutes at room tempera-
ture. Fixed cells were then briefly washed (0.1% BSA in PBS), blocked 
(1% BSA and 0.5% Tween-20) for 1 hour, and incubated with Topro3 
(diluted at 1:1,000 in PBS) for 15 minutes. After washing in PBS, cov-
erslips were mounted facedown onto slides.
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and Mecp2T158M/y T158M–Tg animals; number of beam breaks, distanced 
traveled, and average speed in the open field assay; stance and pro-
pulsion times; and breathing irregularities and number of apneas per 
hour. The rotarod task was analyzed using 2-way ANOVA (P < 0.05). 
Comparison of MeCP2 levels in nucleosolic versus chromatin fractions 
was performed using 2-way ANOVA, followed by Sidak’s post-hoc test. 
MeCP2 protein levels following MG132 treatment were analyzed using 
1-way ANOVA, followed by Dunnett’s multiple comparisons test.
Study approval
Experiments were conducted in accordance with the ethical guide-
lines of the NIH and with the approval of the IACUC of the University 
of Pennsylvania.
Acknowledgments
We thank the Intellectual and Developmental Disability Research 
Center Gene Manipulation Core at the Children’s Hospital of 
Boston (M. Thompson) for the generation of knockin mice and 
the Transgenic and Chimeric Core Facility at the University of 
Pennsylvania (J. Richa) for the generation of Tg mice. This work 
was supported by grants from the NIH (R01 NS081054 and R01 
MH091850, to ZZ) and a Basic Research Award (to ZZ) and a 
Mentored Training Fellowship (to JML), both from RettSyndrome.
org. ZZ is a Pew Scholar in Biomedical Sciences.
Address correspondence to: Zhaolan Zhou, Department of Genet-
ics, University of Pennsylvania Perelman School of Medicine, 415 
Curie Boulevard, Philadelphia, Pennsylvania 19104, USA. Phone: 
215.746.5025; E-mail: zhaolan@mail.med.upenn.edu.
DG’s present address is: Department of Biology, University of 
York, Heslington, York, United Kingdom.
Open field assay. Locomotor activity was measured by beam breaks 
in an arena with a 16 × 16 photobeam array (San Diego Instruments). 
Mice were placed in the middle of the arena, and the number of beam 
breaks, distance travelled, and average speed were quantified over the 
course of 10 minutes in 1-minute bins. Testing was performed under 
dim lighting conditions (15 lux).
Accelerating rotarod. Mice were placed on a rotarod apparatus 
(Harvard Apparatus), accelerating linearly from 4 to 40 rpm for 5 tri-
als a day on 4 consecutive days. Each mouse was allowed at least 10 
minutes of rest between each trial, with each trial lasting a maximum 
of 5 minutes. The amount of time each mouse spent on the rod before 
falling was recorded for each trial.
Treadmill gait analysis. Gait behaviors were assayed using the 
TreadScan System (Clever Sys Inc.). Prior to testing, animals were 
habituated to the testing room for at least 30 minutes and were 
allowed to habituate in the treadmill chamber for 3 minutes. The mice 
were tested for 20 seconds at a constant speed of 18 cm/s. Animals 
who could not maintain this walking speed for the entire 20-second 
duration were excluded from the study. The accompanying TreadScan 
software automatically analyzed gait characteristics.
Statistics
Data are presented as the mean ± SEM. Statistical analyses were per-
formed using GraphPad Prism 6 (GraphPad Software). Brain weight 
comparisons between WT and T158M-knockin mice were analyzed 
using a 2-tailed t test with Bonferroni’s correction. Body weight and 
phenotypic scores for Mecp2T158M mice versus WT controls were ana-
lyzed using a 2-tailed t test. MeCP2 protein levels with developmental 
age were analyzed using a 2-tailed t test. The following measurements 
were analyzed using 1-way ANOVA (P < 0.05), followed, when appro-
priate, by Tukey’s post-hoc test: ChIP-qPCR; total MeCP2 levels, body 
weight, and brain weight for Mecp2+/y, Mecp2+/y T158M–Tg, Mecp2T158M/y, 
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